Oxford University to develop Alzheimer’s disease treatments with Exscientia
19th February 2021
The Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) has announced a partnership with AI drug discovery company Exscientia on the development of therapies for Alzheimer’s disease.
The collaboration will focus on the NLRP3 inflammasome pathway, which has been shown to play a key role in Alzheimer’s pathogenesis.
Exscientia will use its AI-driven technology to generate novel clinical assets targeting this pathway. This will build on years of research by the ARUK-ODDI, which has identified chemical starting points that modulate NLRP3 inflammasome formation.
“We are delighted to be partnering with Exscientia. Their state-of-the-art AI capabilities will enable us to investigate multiple molecules in parallel and accelerate the project towards candidate declaration,” said John Davis, chief scientific officer of the ARUK-ODDI.
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer s disease
Neuroinflammation collaboration targeting inflammasome steps-up-the-pace in race for Alzheimer s disease medicines that alleviate the burden of devastating disease
Exscientia, a leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer s disease (AD).
AD is the most common form of dementia worldwide, with an estimated 44 million people living with AD or related form of dementia.
1,2 Symptoms of this progressive disease are debilitating, distressing for both those with the disease and their loved ones and there is currently no cure.